Phase I study of OGX-011, a second generation antisense oligonucleotide (ASO) to clusterin, combined with cisplatin and gemcitabine as first-line treatment for patients with stage IIB/IV non-small cell lung cancer (NSCLC)

Janessa Laskin,K.N. Chi,B. Melosky,K. Sill,D. Hao,Christina Canil,Martin E. Gleave,Nevin Murray

Phase I study of OGX-011, a second generation antisense oligonucleotide (ASO) to clusterin, combined with cisplatin and gemcitabine as first-line treatment for patients with stage IIB/IV non-small cell lung cancer (NSCLC)

2006

Janessa Laskin
K.N. Chi
B. Melosky
K. Sill
D. Hao
Christina Canil
Martin E. Gleave
Nevin Murray

17078 Background: The clusterin gene is frequently expressed in NSCLC and encodes a cytoprotective chaperone protein that promotes cell survival and is upregulated in response to apoptotic stimuli ...

Keywords:

Oligonucleotide
non-small cell lung cancer (NSCLC)
Sense (molecular biology)
Cisplatin
Cancer research
Gemcitabine
Immunology
Clusterin
Biology
Oncology
Downregulation and upregulation
first line treatment
Chaperone (protein)
Apoptosis
Medicine
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations